CD47 and cancer: The advantages using cancer-CMC-NPs are immune-evading properties (CD47), homotypic targeting behavior (cadherin, integrins), and cancer immunotherapy (vaccination) with improved tumor-specific accumulation, enhanced circulation, and enhanced drug or gene delivery avoiding side effects.